Pure Global
NCT06368986

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

An Open Label, Phase 1 Study to Assess the Effect of Food on Bioavailability for an Investigational Capsid Inhibitor in Healthy Adult Participants
ViiV Healthcare·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
HIV Infections
Drug/Device/Intervention
VH4011499
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
ViiV Healthcare
Timeline & enrollment
Phase
Phase 1
Start date
Apr 16, 2024
End date
Jun 12, 2024
Enrollment
36 participants
Primary outcome

Area under the plasma concentration - time curve from time zero (pre-dose) to infinity time (AUC[0-inf]) of VH4011499,Area under the plasma drug concentration - time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tlast) of VH4011499,Maximum observed plasma drug concentration (Cmax) of VH4011499,Time to maximum observed plasma concentration (Tmax) of VH4011499

Summary

The purpose of this study is to evaluate effect of food (in fasted and fed conditions) on the
 bioavailability of CAI VH4011499.

ICD-10 classifications
HIV disease resulting in other viral infectionsHIV disease resulting in other bacterial infectionsHIV disease resulting in multiple infectionsAcute HIV infection syndromeHIV disease resulting in other infectious and parasitic diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06368986
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06368986 through Pure Global AI's free database. This Phase 1 trial is sponsored by ViiV Healthcare and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.